Case Study
Expanding market access beyond an initial European approval requires more than submitting an existing dossier. Biopharmaceutical companies, like the one featured in this case study, need to carefully adapt to meet country-specific regulatory expectations. Following successful Marketing Authorizations in the EU and UK, the company sought approval for its oncology therapy in Switzerland. The submission required updates reflecting changes made during the EU review process while ensuring alignment with SwissMedic’s administrative, labeling, and technical requirements.
Leveraging prior experience with the product’s European submissions, a cross-functional team provided regulatory strategy, medical writing, publishing, and project leadership to deliver a compliant Swiss Marketing Authorization Application. Through coordinated global collaboration, the team updated key summaries, developed Swiss-specific content, and completed a technically compliant eCTD submission accepted by SwissMedic. Learn how strategic regulatory expertise can streamline EU dossier adaptations and accelerate access to new European markets.
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
or
Please enter your email address and create a password to access the full content, Or log in to your account to continue.
or
Please tell us more about you so that we can customize our newsletters to your specific interests:
What topics interest you? (Check all that apply.)
Leave a Reply